StreetInsider.com News Articles

Dyne Therapeutics closes $431.4M public stock offering

Thu, 23 Jul 2026 16:05:11 -0400

Dyne Therapeutics, Inc. (Nasdaq: DYN) has closed an upsized underwritten public offering of 21,045,000 shares of common stock at $20.50 per share, according to a company statement.

The offering generated gross proceeds of approximately $431.4 million before underwriting discounts, commissions, and other expenses. The total share count includes 2,745,000 shares issued after underwriters exercised their option to purchase additional shares in full. All shares were sold by Dyne.

Morgan Stanley, Jefferies, Evercore ISI, LifeSci Capital, and Raymond James served as joint book-running managers. Jones acted as lead manager.

The offering was conducted under a shelf registration statement filed with the Securities and Exchange

Dyne Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares

Thu, 23 Jul 2026 16:05:00 -0400

WALTHAM, Mass., July 23, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced the closing of its previously announced upsized underwritten public offering of 21,045,000 shares of its common stock at a public offering price of $20.50 per share, which includes 2,745,000 shares issued upon the exercise in full by the underwriters of their option to purchase additional shares of common stock in the offering. The gross proceeds to Dyne from the offering were approximately $431.4 million, before deducting underwriting

Dyne Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares

Thu, 23 Jul 2026 16:05:00 -0400

Cantor Fitzgerald Starts Dyne Therapeutics (DYN) at Overweight

Thu, 23 Jul 2026 07:35:14 -0400

(Updated - July 23, 2026 7:35 AM EDT)

Cantor Fitzgerald analyst Eric Schmidt initiates coverage on Dyne Therapeutics (NASDAQ: DYN) with a Overweight rating.

The analyst commented: "We are initiating coverage of Dyne Therapeutics (NASDAQ: DYN) with an Overweight rating. Dyne is developing treatments for genetically driven neuromuscular diseases using its proprietary FORCE platform, which is designed to improve delivery of nucleic acids and other payloads into muscle and the central nervous system (CNS). We view shares as attractive based upon the following three factors: 1. Z-rostudirsen’s near-term potential in DMD51. Z-rostudirsen targets Duchenne muscular dystrophy (DMD) patients amenable to Exon 51

Cantor Fitzgerald Starts Dyne Therapeutics (DYN) at Overweight

Thu, 23 Jul 2026 07:35:14 -0400

(Updated - July 23, 2026 7:35 AM EDT)

Cantor Fitzgerald analyst Eric Schmidt initiates coverage on Dyne Therapeutics (NASDAQ: DYN) with a Overweight rating.

Form 424B5 Dyne Therapeutics, Inc.

Wed, 22 Jul 2026 17:21:00 -0400

si-local-file:///var/storage/secattach/20260722/26802724.html

Form 424B5 Dyne Therapeutics, Inc.

Wed, 22 Jul 2026 17:21:00 -0400

si-local-file:///var/storage/secattach/20260722/26802724.html

Form 8-K Dyne Therapeutics, Inc. For: Jul 21

Wed, 22 Jul 2026 17:20:00 -0400

si-local-file:///var/storage/secattach/20260722/26802705.html

Form 8-K Dyne Therapeutics, Inc. For: Jul 21

Wed, 22 Jul 2026 17:20:00 -0400

si-local-file:///var/storage/secattach/20260722/26802705.html

Dyne Therapeutics prices $375M public stock offering at $20.50